ACTRN12605000636651已完成1 期
Intratumoural administration of coxsackievirus A21 for the control of malignant melanoma.
Viralytics Ltd.0 个研究点目标入组 3 人开始时间: 2005年10月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- ot stated 至 ot stated（—）
- 性别
- All
入选标准
- •Stage IV melanoma (AJCC)- minimum of 2 SC metastases- failure or refusal of standard chemotherapy- ECOG score of 0 or 1- other.
排除标准
- •Metastatic CNS disease- occular or mucosal melanoma- immunodeficiency- splenectomy- other.
研究者
相似试验
已完成
1 期
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)Malignant MelanomaNCT00235482Viralytics3
进行中（未招募）
2 期
Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological MalignanciesGenital Neoplasms, FemaleNCT05051696Liu Zi120
招募中
1 期
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT05901285Vaxiion Therapeutics48
已完成
1 期
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)Breast CancerProstate CancerMelanomaNCT00636558Viralytics8
已完成
1 期
Talimogene Laherparepvec in Patients With Unresectable Pancreatic CancerPancreatic CancerNCT00402025BioVex Limited17